Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years
2023-508504-38-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Liraglutide 3.0 mg (Saxenda) with Placebo (2 arms). Primary endpoint: Relative change in BMI from baseline to week 56. Planned start Jan 2024; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2023-508504-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508504-38-00.